Streetbeat News

Regulatory

BWEN

MKTX

Broadwind Inc (BWEN) has agreed to sell approximately $15 million of Advanced Manufacturing Production Credits to MarketAxess Holdings, Inc. (MKTX) under the Inflation Reduction Act. The tax credits are related to Broadwind's domestic production and sale of wind turbine components. Broadwind will also sell section 45X tax credits generated in 2024 on a quarterly basis. CEO Eric Blashford highlighted the economic incentive for renewable energy investment provided by the 45X tax credit. BWEN's stock saw a slight increase of 0.35% in premarket trading.

Portfolio Pulse from Shivani Kumaresan

December 27, 2023 | 1:52 pm

CHRS

Coherus BioSciences' stock is trading higher following the announcement of FDA approval for UDENYCA ONBODY, a pegfilgrastim-cbqv product.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:46 pm

SPY

VGK

Fitch Ratings reports that default rates for high yield bonds and leveraged loans are expected to rise in the U.S. and Europe in 2024 due to weaker economic growth and high interest rates. U.S. leveraged loan defaults increased from 1.6% at the end of 2022 to 3.04% in 2023, and high yield bond defaults rose from 1.35% to 2.99%. European leveraged loan defaults are projected to reach 4% by the end of 2024, with high yield bond defaults also expected to increase. The forecast reflects sector-specific issues in healthcare, pharmaceuticals, telecom, technology, consumer, industrial, and real estate sectors.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:43 pm

VTGN

Vistagen Therapeutics (NASDAQ: VTGN) is set to receive a patent from the European Patent Office for AV-101, a treatment for neuropathic pain. Preclinical studies show AV-101 has effects similar to gabapentin but with fewer side effects. Phase 1 clinical trials indicate AV-101 is well-tolerated with no significant adverse events compared to placebo. The patent will extend until at least 2034, enhancing Vistagen's global patent portfolio. The company is seeking strategic collaborations to advance AV-101's clinical development and commercialization. The FDA has granted Fast Track designation for AV-101 as a non-opioid treatment for neuropathic pain.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:30 pm

PWUPU

Trading for PWUPU was halted and then resumed at 8:30 AM ET, with updated status including news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:30 pm

IOVA

Iovance Biotherapeutics' stock is trading lower following the FDA's clinical hold on the IOV-LUN-202 trial due to a Grade 5 adverse event potentially related to the trial's pre-conditioning regimen.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:25 pm

PWUP

Trading for PWUP was halted and then resumed at 8:25 AM ET, with an update on news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:25 pm

ENVB

Enveric Biosciences has reported progress on the preclinical development of its lead prodrug candidate, EB-373, as of year-end. The company anticipates completing all preclinical activities for EB-373 by Q1 of 2024, setting the stage for a first-in-human clinical trial.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:06 pm

NKGN

NKGen Biotech has received a No Objection Letter from Health Canada for a Phase 1/2A clinical trial of SNK01, a natural killer cell therapy for moderate Alzheimer's disease. The first interim data from the trial is expected in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:03 pm

PWUPU

Trading for PWUPU was halted at 7:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material news.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 12:55 pm